From TokenPost · · 40s
Jaguar Health Targets Mid-2027 MVID Filing
Jaguar Health aims for mid-2027 drug submission after $10m debt cut.
In brief
Jaguar Health aims for mid-2027 drug submission after $10m debt cut. Jaguar Health plans mid-2027 new drug application for pediatric MVID treatment after reducing debt by over $10 million. Originally reported by TokenPost.
Jaguar Health Targets MVID Filing
Jaguar Health plans mid-2027 new drug application for crofelemer to treat pediatric MVID after completing pivotal-trial enrollment.
Debt Reduction Milestone
Jaguar reduced outstanding debt by more than $10 million in Q3 2026, with $2.343 million revenue and $9.23 net loss per share.
Next Milestone
Jaguar targets mid-2027 NDA submission and seeks FDA breakthrough therapy designation for faster review.
At a glance
Jaguar Health plans mid-2027 new drug application for pediatric MVID treatment after reducing debt by over $10 million.
Read the TL;DR — this story on one card.






